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ABSTRAK
Latar belakang: meningkatnya kadar alfa fetoprotein (AFP) serum seringkali ditemui pada pasien karsinoma 
sel hati (KSH) tahap lanjut. Cluster Differentiation 44 (CD44) dan CD90 adalah biomarker sel punca yang diduga 
merupakan penanda awal KSH dan berhubungan dengan onset dan progresivitas KSH. Hingga kini masih belum ada 
studi terkait sel punca KSH di Indonesia. Studi ini bertujuan untuk mengevaluasi ekspresi penanda sel punca kanker 
CD44, CD90 dan kadar AFP pada pasien dengan penyakit hati lanjut. Metode: studi observasional dilakukan pada 
41 pasien dengan hepatitis B dan/ atau C kronis, sirosis hati, dan KSH di RSUD dr. Saiful Anwar Malang. Ekspresi 
CD44 dan CD90 dalam darah diukur menggunakan flow cytometri dan kadar AFP serum menggunakan ELISA. Data 
karakteristik pasien dilakukan analisa statistik bivariat dan multivariat (One way ANOVA, Mann-Whitney, Chi-Square, 
Kruskal-Wallis). Data CD44, CD90 dan AFP dianalisis menggunakan uji Kruskal Wallis dengan signifikansi p<0,05, 
serta uji kekuatan diagnostik dengan analisis receiver operating characteistic (ROC). Hasil: subjek penelitian ini 
adalah 16 pasien hepatitis kronis, 15 pasien sirosis hepatis, dan 10 pasien KSH. CD44+CD90+ dan AFP pada ketiga 
kelompok mempunyai perbedaan signifikan (p=0.001; p=0.000), khususnya pada hepatitis kronis yang dibandingkan 
dengan sirosis hepatis (p=0.002; p=0.000) dan KSH (p=0.002; p=0.000). Analisa ROC menunjukkan kekuatan 
diagnostik paling baik pada kombinasi CD44+CD90+ dengan AFP (AUC=0.981; p=0.000;). Kesimpulan: ekspresi 
CD44+CD90+ dan kadar AFP serum pada pasien dengan KSH lebih tinggi dibandingkan hepatitis kronis dan sirosis 
hepatis. Kombinasi kedua parameter ini memiliki kekuatan diagnostik KSH yang paling baik.
Kata kunci: alfa fetoprotein (AFP), biomarker, hepatitis kronis, sirosis hepatis, karsinoma sel hati.
ABSTRACT
Background: increased serum alpha fetoprotein (AFP) levels are often found in patients with advanced 
hepatocellular carcinoma (HCC). Cluster Differentiation 44 (CD44) and CD90 are stem cell biomarkers 
that have been assumed as the early HCC markers and associated with onset and progressivity of HCC. The 
study related to HCC stem cell has not been available in Indonesia. The present study aimed to evaluate the 
expression of cancer stem cell markers (CD44, CD90) and AFP levels in patients with advanced liver disease. 
Methods: an observational study was conducted in 41 patients with chronic hepatitis B and/or C infection, 
liver cirrhosis, and HCC at dr. Saiful Anwar General Hospital. CD44 and CD90 expressions were measured 
with flow cytometry, and AFP serum levels with ELISA. Data on patient characteristics were evaluated using 
bivariate and multivariate statistical analysis (One-way ANOVA, Mann-Whitney, Chi-Square, Kruskal-Wallis). 
Data of CD44, CD90 and AFP were analyzed using Kruskal Wallis test with a significance value of p<0.05, 
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and diagnostic power was analyzed using receiver operating characteristic (ROC). Results: the subjects of our 
study were 16 patients with chronic hepatitis, 15 patients with liver cirrhosis, and 10 patients with HCC. There 
was a significant difference regarding CD44+CD90+ and AFP among those three groups (p=0.001; p=0.000) 
specifically in chronic hepatitis compared to liver cirrhosis (p=0.002; p=0.000) and HCC (p=0.002; p=0.000) 
respectively. ROC analysis showed the best diagnostic power for the combination of CD44+CD90+ and AFP 
(AUC=0.981; p=0.000). Conclusion: there are higher expressions of CD44+CD90+ and serum AFP levels 
in patients with HCC compared to the other two groups (those with chronic hepatitis and liver cirrhosis). The 
combination of both parameters has the best diagnostic power of HCC.
Keywords: alpha fetoprotein (AFP), biomarker, chronic hepatitis, liver cirrhosis, hepatocellular carcinoma.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth 
most frequent cancer in the world and third most 
common cause of cancer death. The incidence of 
HCC in Asian countries is directly proportional 
to increased incidence of chronic hepatitis B 
and C.1-3 Host factors, viral infection, lifestyle 
and diet may have impacts on the development 
of HCC and it may also have contribution on 
epigenetic changes involved in the development 
of normal stem cells programming during 
cellular differentiation. Epigenetic deregulation 
causes loss of stem cell differentiation during 
the course of cancer pathogenesis, which 
further develops into cancer stem cells (CSCs). 
The development of CSCs is affected by the 
activation of hepatocarcinogenesis signaling 
pathway. It is suspected that the progression of 
advanced liver disease into HCC occurs as a 
result of the ability of cancer stem cells to self-
renew, proliferate and maintain tumor growth.4,5 
Regular monitoring of high-risk patients is 
one of the efforts aimed at early diagnosis of 
HCC and it has high likelihood of recovery. The 
regular monitoring consists of ultrasonography 
and/ or evaluation of tumor markers. Based on 
the APASL guideline, periodic monitoring of 
liver cirrhosis patients includes evaluating alpha 
fetoprotein (AFP) levels and monitoring using 
abdominal ultrasound every 6 months.3 While the 
AASLD guideline recommends only abdominal 
ultrasound for monitoring without evaluating 
serum AFP levels.6,7
Serum alpha fetoprotein (AFP) levels is 
the most common diagnostic marker for HCC. 
AFP levels of greater than 200 ng/mL are highly 
suggestive of malignancy as they have been found 
in 60-70 % of HCC patients. Nevertheless, it 
should be noted that a single AFP serum levels 
in regular monitoring has low sensitivity and 
specificity, and increased levels may not be fund 
in patients with HCC who have tumor diameter of 
less than 3 cm. The limitations of AFP has lead to 
the use of ultrasound examination as an additional 
method for detecting HCC.7 The combination of 
AFP and ultrasound examination may be effective 
for screening and diagnosis of HCC; however, it 
is still limited for detection. It has been known 
that the sensitivity of ultrasonography in the early 
detection of HCC ranges from 45%; while the 
combination of ultrasonography and AFP ranges 
from 63%.8 It indicates the need for additional 
modalities in HCC detection and prognostic 
assessment.
CSCs may become another alternative HCC 
diagnosis as they have the capacity for self-
renewal, proliferation and maintaining tumor 
growth.2 CSCs can be marked using variety of 
biomarkers, such as: CD13, CD24, CD44, CD90, 
CD133, DLK1, and EpCAM. Expressions of 
these markers are associated with resistance 
to chemotherapy agents.9 Increased CD44 and 
CD90 expressions are thought to be associated 
with onset, progression, and early signs of 
HCC.1,2 Nowadays, the newly developed therapy 
using stem cell for liver disease also carry the 
risk and the potential to develop into CSCs.10 
Until now, no research has been conducted in 
Indonesia that studied about HCC stem cells as 
a potential early diagnostic test that may affect 
patient outcomes. Our cohort study explored the 
value of HCC stem cell marker expression in 
relation to advanced liver disease.
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METHODS
Our cross-sectional study was conducted 
between 2016 and 2017 at dr. Saiful Anwar 
General Hospital Malang, Indonesia. Subjects 
were 41 patients with chronic hepatitis B and/ 
or C infection, either with or without liver 
cirrhosis and HCC. Subjects were divided into 3 
groups: a chronic hepatitis group, a liver cirrhosis 
group and a HCC group based on a series of 
physical examinations and investigations. The 
investigations included complete blood count, 
liver function, physiological hemostasis as well 
as HBsAg and anti HCV serological tests, AFP, 
abdominal ultrasound and abdominal CT scan 
whenever necessary. Diagnosis of hepatitis B 
and/ or C was made if HBsAg and/ or anti HCV 
was reactive. Liver cirrhosis was defined if there 
was a decreased in synthetic liver function and 
detoxification capability, which was also marked 
by portal hypertension, portal vein and collateral 
circulation. HCC was established when serum 
AFP levels were ≥200 ng/ml and nodules were 
present in the liver on ultrasound examination or 
abdominal CT scan. Inclusion criteria were: age 
>20 years, patients were diagnosed with chronic 
hepatitis B and/ or C infection without or with liver 
cirrhosis or HCC. The exclusion criteria were had 
a malignancy other than HCC or metastasis in the 
liver, and pregnancy.
Venous blood samples (10 mL) were 
obtained from each subject and then were 
collected in heparinized tubes. The first 5 cc of 
venous blood samples were used for examining 
CD44 and CD90 expressions, which was 
performed at the Physiology Laboratory of 
Faculty of Medicine, University of Brawijaya 
Malang. The examination included the isolation 
of peripheral blood mononuclear cells, which 
was followed by staining process using PE anti-
human CD44 produced by Bio-Legend and FITC 
anti-human CD90 produced by Bio-Legend of 
Gamma Scientific Biolab Ltd., and the reading 
was performed using flow cytometer by BD 
FACS Calibur. The remaining 5 cc of venous 
blood sample were sent for serum AFP test using 
ELISA method to Prodia Laboratory in Malang. 
The normal range of serum AFP levels is < 20 
ng/mL.11 CD44+ expression in peripheral blood 
of healthy subject was 46.1±13.4%;12 while 
CD90+ expression in cultured mononuclear cells 
of healthy subjects was 0.48%.13
Data on subject characteristics were presented 
as mean (SD) and percentage. One way ANOVA 
was performed when there was normal data 
distribution; while Kruskal Wallis test was used 
when the distribution was not normal. Chi Square 
tests were used for both nominal scale parameters. 
Mann Whitney test was performed when the 
criteria for Chi Square test was not fulfilled. Data 
was considered significant when p <0.05.
CSCs and AFP data were presented as mean 
and interval quartile range (IQR) since there 
was a wide range of data. Kruskal Wallis test 
was used since the distribution of data was not 
normal and the data was considered significant 
when p <0.05. The test was then followed by the 
post-hoc Mann Whitney test.
ROC curve analysis was performed for 
CSCs and AFP parameters. Parameters with a 
significant value p<0.05 were evaluated further 
to measure the cut-off value using the Youden’s 
index and their sensitivities and specificities were 
determined.
This study has been approved by the Ethics 
Committee of dr. Saiful Anwar Hospital with a 
reference number 400/79/K.3/302/2017.
RESULTS
Sixteen patients had chronic hepatitis, 15 
had liver cirrhosis, and 10 had HCC. All of them 
had no history of alcohol consumption. Other 
characteristics are shown in Table 1.
Comparison of Stem Cell Marker Expression 
on Blood Mononuclear Cells and Serum 
AFP Levels in Patients with Advanced Liver 
Disease
Express ion  o f  CD44+CD90+ was 
significantly different among groups (p=0.001); 
however, theexpression of CD44+CD90- and 
CD44-CD90+ were not.
The mean of CD44+CD90+ expression had a 
tendency to increase with disease progressivity. 
We found a significant difference when we 
compared the chronic hepatitis group and the 
liver cirrhosis group (p=0.002) as well as when 
we compared the hepatitis group and the HCC 
group (p=0.002). In contrast, there was no 
significant difference between the cirrhosis group 
Syifa Mustika                                                                                                               Acta Med Indones-Indones J Intern Med
140
and the HCC group (p=0.657).
A comparative analysis of serum AFP 
levels using a cut off of 200 ng/mL among 
chronic hepatitis group, liver cirrhosis and HCC 
revealed significant difference (p=0.000). Post 
hoc analysis showed that there was significant 
difference between chronic hepatitis group 
compared to liver cirrhosis (p=0.000), as well 
as in the hepatitis group compared to the HCC 
group (p=0.000). But there was no significant 
difference between the cirrhosis group and HCC 
(p=0.185).  Data of CSCs expressions and serum 
AFP levels are shown in Table 2.
Comparison between Diagnostics Power of 
Cancer Stem Cell and  AFP
ROC test was generated to analyze the 
diagnostic power of CSCs and AFP. Results are 
shown in Figure 1-5. We found that CD44+CD90- 
and CD44-CD90+ did not have significant 
p value and AUC value was low (p=0.903, 
AUC=0.487 and p=0.249, AUC=0.377) (Figure 
1 and Figure 2); while CD44+CD90+ and AFP 
Table 1. Subject characteristics
Clinical Characteristics
Advanced Liver Disease
p^Chronic Hepatitis 
(n=16)
Liver Cirrhosis 
(n=15)
Hepatocellular 
Carcinoma (n=10)
Age, mean (SD) 42,68 (14.84) 52,2  (9.39) 60,10 (10.51) 0.003*
Sex
 - Male 10 (62.5%) 14 (93.33) 9 (90.0) 0.262#
 - Female 6 (37.5%) 1 (6.67) 1 (10.0)
Antiviral Hepatitis Therapy
 - Yes 14 (87.5%) 5 (33.33) 0 (0.0) 0.000†
 - No 2 (12.5%) 10 (66.67) 10 (100)
Length of therapy (weeks), mean (SD) 62.81 (62.41) 14.93 (31.8) 0 0.000‡
Smoking Status, n (%)
 - Not smoking 10 (62.5) 7 (46.67) 4 (40.0)
 - Mild (4.29 sticks/day) 2 (12.5) 2 (13.33) 1 (10.0) 0.223‡
 - Moderate (12 sticks/days) 4 (25.0) 6 (40.0) 2 (20.0)
 - Heavy (32 sticks/day) 0 (0.0) 0 (0.0) 3 (30.0)
Duration of smoking (years), mean 
(SD)
8.25 (12.90) 14.07 (15.93) 21.8 (20.58) 0.204‡
Body Mass Index (kg/m2), n (%)
 - Underweight 1 (6.3) 1 (6.7) 6 (60.0)
 - Normal 6 (37.5) 7 (46.7) 3 (30.0)
 - Overweight 3 (18.8) 0 (0.0) 1 (10.0) 0.009‡
 - Obesity 1 5 (31.3) 6 (40.0) 0 (0.0)
 - Obesity 2 1 (6.3) 1 (6.7) 0 (0.0)
Viral Hepatitis Infection Type, n (%)
 - Hepatitis B 11 (68.8) 11 (73.3) 10 (100.0)
 - Hepatitis C 5 (31.3) 3 (20.0) 0 (0.0) 0.161‡
 - Hepatitis B and C 0 (0.0) 1 (6.7) 0 (0.0)
AST (U/L), mean (SD) 63.25 (37.68) 73 (54.27) 143.2 (108.32) 0.023‡
ALT (U/L), mean (SD) 60.94 (39.66) 69.13 (72.97) 54.8 (48.17) 0.671‡
Albumin serum (g/dL), mean (SD) 3.9 (0.10) 3.09 (0.22) 3.07 (0.26) 0.002*
Child Turcotte Pugh Score, n (%)
 - A 8 (53.3) 3 (30.0)
 - B 6 (40) 5 (50.0) 0.201#
 - C 1 (6.7) 2 (20.0)
^ Significant with p<0.05; * One-way ANOVA test; † Chi-square test; ‡ Kruskal-Wallis test; # Mann-Whitney test.
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Table 2. CSCs expressions and serum AFP levels in patients with advanced liver disease
Blood Mononuclear Cell 
Marker Expression
Chronic Hepatitis 
(n=16)
Liver Cirrhosis  
(n=15)
Hepatocellula Carcinoma 
(n=10) p^
CD44+CD90- (% gated), 
median (IQR) 9.55 (0.038-1.04)** 22.37 (0.48-28.78) 8.68 (0.26-17.67) 0.09 
‡
CD44-CD90+ (% gated), 
median (IQR) 11.86 (5.97-22.04) 7.32 (2.34-10.32) 5.45 (1.85-6.36) 0.225 
‡
CD44+CD90+ (% gated), 
median (IQR) 0.73 (0.28-1.19) 8.29 (1.38-6.92)** 10.35 (1.77-10.72) 0.001 
‡
Serum α-fetoprotein, median 
(IQR) 7.25 (1.47-8.20) 27.00 (3.20-30.00) 13088.55 (216.25-23914.00) 0.000 
‡
 - ≤ 200 ng/mL, n (%) 16 (100.0) 15 (100.0) 3 (30.0)
 - > 200 ng/mL, n (%) 0 (0.0) 0 (0.0) 7 (70.0)
^ Significant with p<0.05; ‡ Kruskal-Wallis test; ** Mean value was higher than Q3
Figure 1. ROC curve of CD44+CD90- (p=0.903, AUC=0.487) Figure 2. ROC curve of CD44-CD90+ (p=0.249, AUC=0.377)
Figure 3. ROC curve of CD44+CD90+ (p=0.042, AUC=0.716) Figure 4. ROC curve of AFP (p=0.000, AUC=0.971)
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had significant p value in addition to moderate 
and high value of AUC (p=0.042, AUC=0.716 
and p=0.000, AUC=0.971) (Figure 3 and Figure 
4). The results were analyzed further  to compare 
the diagnostic power of CD44+CD90+ only 
(Figure 3), AFP only (Figure 4) and combination 
of both (Figure 5). Our study showed that the 
combination of CD44+CD90+ with AFP had 
significant results with very high diagnostic 
power (p=0.000, AUC=0.981). Data was further 
evaluated to measure the cut-off value using the 
Youden’s index; moreover, the sensitivity and 
specificity were determined. Detailed results are 
shown in Table 3. 
DISCUSSION
Comparison of Cancer Stem Cells and Serum 
AFP levels in Patients With Advanced Liver 
Disease
There was no significant difference of 
CD44+CD90- expression among the chronic 
hepatitis, liver cirrhosis and HCC groups. Naor 
et al in their previous study showed that single 
expression of CD44+ between cancer and control 
groups did not significantly differ.14 Jaggupilli et 
al also showed that single expression of CD44+ is 
not a marker for carcinogenesis since the CD44+ 
is expressed in almost all normal cells as well 
as cancer cells.15 A recent study showed that 
CD44-CD90+ expression among patients with 
chronic hepatitis, liver cirrhosis and HCC did 
not differ significantly. Sun et al. demonstrated 
that progenitor cells or normal adult hepatic stem 
cells also express CD90+.16 However, Yang et al 
explained that blood samples of HCC patients 
with normal serum AFP levels expressing CD45-
CD90+ still indicates the presence of cancer 
stem cells.17
Our study demonstrated that  there 
were significantly different expressions of 
CD44+CD90+ among the HCC, chronic 
hepatitis and liver cirrhosis groups. Romano et 
al showed that CD44+ expression along with 
other CSCs markers could better determine 
HCC phenotype of stem cell surface; moreover, 
they also showed that double expression of 
CD44 and CD90 defined more aggressive 
phenotype of HCC.18 Yang et al11 conducted a 
multiparametric analysis and found that most 
HCC cells that have CD90+ expression also 
have CD44+ expression. Sun-et al.16 suggested 
that cells with CD44+CD90+ expressions have 
more aggressive behavior than CD44-CD90+ 
cells and have higher levels of tumorigenicity 
and ability to form metastatic lesions in those 
with immunodeficiency conditions.
Our results regarding serum AFP levels in 
HCC group, which was compared to the serum 
levels in chronic hepatitis and liver cirrhosis 
groups, was substantially different from the 
results in a study conducted by Marrero et al 
that showed increased serum AFP levels in 
HCC patients.19 AFP serum levels < 400 ng/
mL indicates a low sensitivity in detection of 
HCC, which may explain that a third of HCC 
patients may be undetected and have subclinical 
Figure 5. ROC curve of CD44+CD90+ with AFP (p=0.000, 
AUC=0.981)
Table 3. ROC curve analysis and cut off value of CD44+CD90+, AFP, and combination of CD44+CD90+ and AFP
Test Cut off value AUC SE Sensitivity Specificity P value 95 % CI
CD44+CD90+ 1.77% gated 0.716 0.095 0.042 0.529 - 0.903
AFP 144.3 ng/mL 0.971 0.022 70% 100% 0.000 0.927 - 1.000
CD44+CD90+ and AFP 1.77% gated and or 144.3 ng/mL 0.981 0.017 100% 93.55% 0.000 0.946 - 1.000
AUC: Area Under Curve; SE: Standard Error; CI: Confidence Interval
Vol 51 • Number 2 • April 2019                        The expressions of CD44, CD90 and alpha fetoprotein biomarkers
143
diagnosis.6 Thus, AFP serum levels are not 
associated with HCC prognosis such as tumor 
size, stage, or disease progression.18
Comparison of the Diagnostics Power of 
Cancer Stem Cell with AFP
Our study showed the smallest size of AUC 
for CD44+CD90+ biomarker and the greatest 
size for the combination of CD44+CD90+ and 
AFP levels which indicates that the combined 
biomarkers have the highest value sensitivity and 
specificity. The cut off value of CD44+CD90+ 
was 1.77% gated, which was based on the 
Youden’s index. Such range was also found in 
the liver cirrhosis group, but not in the hepatitis 
group. There was a wide range of values for 
CD44+CD90+ measurement and the sensitivity 
was as low as the sensitivity of AFP levels; 
however, the specificity was lower than the 
specificity of AFP levels. It might occur due to 
less homogeneous samples and small sample 
size.
In our study, we found a great size of AUC, 
which was 0.971 for AFP levels as a biomarker 
with a sensitivity of 70% and an optimal cut-off 
value of 144.6 ng/mL. An earlier study suggested 
a range of cut off value of AFP serum level for 
diagnosis of HCC starting from 20 ng/mL with 
a sensitivity of 62% and specificity of 90.2%.20 
Another study demonstrated that the cut off 
value of AFP serum levels for diagnosis of HCC 
was 20.45 ng/mL with 73% sensitivity and 92% 
specificity.21 These findings support the results 
of our study and we can say that although AFP 
has still been widely used as a diagnostic tool 
of HCC, but it is not a sensitive test. Increased 
AFP serum levels are often found in HCC with 
large tumors,  spread to biliary system, massive 
and diffuse and presence of portal venous 
thrombosis.18 It suggests that AFP as a single 
tools for early diagnosis of HCC is poor and 
therefore, we require a combination of alternative 
agents such as a cancer stem cells biomarkers.
The combination of serum AFP levels 
and CD44+CD90+ expressions appears to 
be the tests that have the best sensitivity and 
specificity. Moreover, we can say that it is the 
best diagnostic parameter compared to AFP 
levels only or CD44+CD90+ expression only. 
Liu et al. conducted a meta-analysis of studies 
regarding the relationship between cancer stem 
cell expression and differentiation of liver cell 
carcinoma. The study found that there was a 
relationship between CD44, CD90, CD133, 
EpCAM cancer stem cells with high AFP values 
in patients with liver cell carcinoma (OR 1.63, 
95% CI=1.36-1.95, p<0.00001).22 Stem cells 
cancer has heterogenity and complexity related 
to biological structure and its nature. Studies 
using liver cancer stem cell markers in liver 
cell carcinoma with the same cell pathway, will 
provide comprehensive screening of liver cancer 
stem cell images.23 Therefore, the expressions 
of CD44+CD90+, which show significant 
different results among population of patients 
with chronic hepatitis, liver cirrhosis, and liver 
cell carcinoma, may serve as the biomarkers for 
diagnosis, prediction, prognosis and indicators of 
progression of liver disease, particularly when it 
is used in combination with AFP levels. Patients 
with chronic hepatitis, hepatic cirrhosis, and liver 
cell carcinoma who have CD44+CD90+ cancer 
stem cell expression will be at risk of developing 
progressive liver disease.
Our study was limited by the small numbers of 
samples. Moreover, another limitation to our study 
is that we only performed a single examination 
of CD44 and CD90 expression. We could not 
evaluate the role of cancer stem cell markers as 
a prognostic factor of HCC yet. We hope that 
results of our cohort study may also enlighten 
our colleagues to have better understanding about 
cancer stem cell marker as potential prognostic 
tool for advanced liver disease.
CONCLUSION
There are higher expressions of CD44+CD90+ 
cancer stem cells (CSCs) markers and serum AFP 
levels in patients with HCC compared to those 
with chronic hepatitis and liver cirrhosis. The 
combination of CD44+CD90+ expressions and 
AFP has the best diagnostic power of HCC.
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